+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli



Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli



Journal of Clinical Microbiology 46(2): 817-820



A 25-year-old female was admitted to our intensive care unit with septic shock and multiorgan failure caused by extended-spectrum beta-lactamase-producing Escherichia coli originating from the right renal pelvis. A 16-day course of treatment with meropenem reversed the septic condition, but the infection recurred thereafter. The patient recovered fully after therapy was changed to tigecycline.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056683384

Download citation: RISBibTeXText

PMID: 18077630

DOI: 10.1128/JCM.01340-07


Related references

Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Journal of Antimicrobial ChemoTherapy 65(9): 2048-2049, 2010

Clinical characteristics of urosepsis caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumonia and their emergence in the community. Journal of Microbiology, Immunology, and Infection 45(2): 127-133, 2012

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clinical Microbiology and Infection 16(2): 132-136, 2010

Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, Spain. International Journal of Antimicrobial Agents 28(6): 532-536, 2006

Successful treatment of a rare extended retroperitoneal necrotizing soft tissue infection caused by extended-spectrum beta-lactamase-producing Escherichia coli: A case report. Medicine 95(49): E5576, 2017

Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagnostic Microbiology and Infectious Disease 56(3): 313-315, 2006

Use of cefepime for the treatment of infections caused by extended spectrum: beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Singapore Medical Journal 48(6): 600-601, 2007

In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. PharmacoTherapy 28(3): 295-300, 2008

Activities of Fosfomycin, Tigecycline, Colistin, and Gentamicin against Extended-Spectrum-beta-Lactamase-Producing Escherichia coli in a Foreign-Body Infection Model. 2013

Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis. International Journal of Infectious Diseases 16(1): E47-E52, 2012

Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli. International Journal of Antimicrobial Agents 36(3): 284-287, 2010

Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters. Journal of Microbiology, Immunology, and Infection 49(2): 208-215, 2016

Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrobial Agents and ChemoTherapy 54(9): 4006-4008, 2010

Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Archives of Internal Medicine 168(17): 1897-1902, 2008

In vitro activity of tigecycline and molecular characterization of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates from a university hospital in south-western Germany. ChemoTherapy 58(3): 241-248, 2013